These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 24128969)

  • 1. Evaluating promotional claims as false or misleading.
    Brushwood DB; Knox CA; Liu W; Jenkins KA
    Am J Health Syst Pharm; 2013 Nov; 70(21):1941-4. PubMed ID: 24128969
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The ban on "off-label" pharmaceutical promotion: constitutionally permissible prophylaxis against false or misleading commercial speech?
    Greenwood K
    Am J Law Med; 2011; 37(2-3):278-98. PubMed ID: 21847882
    [TBL] [Abstract][Full Text] [Related]  

  • 3. After Amarin v FDA: What Will the Future Hold for Off-label Promotion Regulation?
    Mackey TK; Liang BA
    Mayo Clin Proc; 2016 Jun; 91(6):701-6. PubMed ID: 27084416
    [No Abstract]   [Full Text] [Related]  

  • 4. FDA actions against misleading or unsubstantiated economic and quality-of-life promotional claims: an analysis of warning letters and notices of violation.
    Stewart KA; Neumann PJ
    Value Health; 2002; 5(5):390-7. PubMed ID: 12201856
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Off-label drug use and promotion: balancing public health goals and commercial speech.
    Kesselheim AS
    Am J Law Med; 2011; 37(2-3):225-57. PubMed ID: 21847880
    [No Abstract]   [Full Text] [Related]  

  • 6. Off-label promotion: government theories of prosecution and facts that drive them.
    Burroughs AD; Levy MC; Schwab GG; Paik Y
    Food Drug Law J; 2010; 65(3):555-88. PubMed ID: 24479242
    [No Abstract]   [Full Text] [Related]  

  • 7. Regulation of prescription drug promotion: direct-to-consumer advertising.
    Baylor-Henry M; Drezin NA
    Clin Ther; 1998; 20 Suppl C():C86-95. PubMed ID: 9915094
    [TBL] [Abstract][Full Text] [Related]  

  • 8. United States v. Caronia: The increasing strength of commercial free speech and potential new emphasis on classifying off-label promotion as "false and misleading".
    Scheineson MJ; Cuevas G
    Food Drug Law J; 2013; 68(2):201-16, iii. PubMed ID: 24640469
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmaceuticals and medical devices: FDA oversight. End-of-year issue brief.
    Chaps NA
    Issue Brief Health Policy Track Serv; 2010 Jan; ():1-31. PubMed ID: 20217914
    [No Abstract]   [Full Text] [Related]  

  • 10. Pharmaceuticals and medical devices: FDA oversight. Issue brief.
    Thomson Reuters/West
    Issue Brief Health Policy Track Serv; 2011 Jan; ():1-39. PubMed ID: 21374841
    [No Abstract]   [Full Text] [Related]  

  • 11. Hidden truth: The perils and protection of off-label drug and medical device promotion.
    Conko G
    Health Matrix Clevel; 2011; 21(1):149-87. PubMed ID: 21847900
    [No Abstract]   [Full Text] [Related]  

  • 12. Bias at the gate?: The pharmaceutical industry's influence on the federally approved drug compendia.
    Gabrielsen L
    Am J Law Med; 2014; 40(1):141-63. PubMed ID: 24844045
    [No Abstract]   [Full Text] [Related]  

  • 13. Origins of the prohibition against off-label promotion.
    Coleman TS
    Food Drug Law J; 2014; 69(2):161-236, i. PubMed ID: 25163210
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The future of off-label marketing regulations in the post-Sorrell era.
    Iraggi J
    Seton Hall Law Rev; 2013; 43(3):1137-63. PubMed ID: 23802338
    [No Abstract]   [Full Text] [Related]  

  • 15. Truth, Falsity, and Fraud: Off-Label Drug Settlements and the Future of the Civil False Claims Act.
    Krause JH
    Food Drug Law J; 2016; 71(3):401-40. PubMed ID: 29140064
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Off-label prescription advertising, the FDA and the First Amendment: a study in the values of commercial speech protection.
    Klasmeier C; Redish MH
    Am J Law Med; 2011; 37(2-3):315-57. PubMed ID: 21847884
    [No Abstract]   [Full Text] [Related]  

  • 17. A Legislative/Legal History of Prescription Drug Advertising and Promotion Regulation.
    Li S; Gibbs I
    J Pharm Pharm Sci; 2021; 24():381-389. PubMed ID: 34314671
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Commercial speech and off-label drug uses: what role for wide acceptance, general recognition and research incentives?
    Gilhooley M
    Am J Law Med; 2011; 37(2-3):258-77. PubMed ID: 21847881
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulating off-label promotion of medications: has the pendulum swung too far?
    Hoffman MB; Yentzer BA; Feldman SR
    Skin Therapy Lett; 2015; 20(3):1-4. PubMed ID: 26382556
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Off-Label Marketing's Audiences: The 21
    Halabi SF
    Am J Law Med; 2018 May; 44(2-3):181-196. PubMed ID: 30106659
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.